1. Home
  2. CTS vs ANAB Comparison

CTS vs ANAB Comparison

Compare CTS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTS Corporation

CTS

CTS Corporation

HOLD

Current Price

$52.37

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$54.34

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTS
ANAB
Founded
1896
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
CTS
ANAB
Price
$52.37
$54.34
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$62.20
AVG Volume (30 Days)
180.3K
408.5K
Earning Date
05-13-2026
04-06-2026
Dividend Yield
0.30%
N/A
EPS Growth
15.87
15.79
EPS
2.19
N/A
Revenue
$541,318,000.00
$91,280,000.00
Revenue This Year
$5.55
$135.51
Revenue Next Year
$5.00
N/A
P/E Ratio
$24.37
N/A
Revenue Growth
4.95
432.03
52 Week Low
$34.02
$14.01
52 Week High
$59.66
$57.74

Technical Indicators

Market Signals
Indicator
CTS
ANAB
Relative Strength Index (RSI) 48.59 57.44
Support Level $40.41 $43.67
Resistance Level $59.66 $57.65
Average True Range (ATR) 1.76 3.50
MACD -0.67 0.03
Stochastic Oscillator 9.27 68.78

Price Performance

Historical Comparison
CTS
ANAB

About CTS CTS Corporation

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEM) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China; Singapore; the Czech Republic; Taiwan, Denmark, and other countries.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: